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QUESTION
My patient has thrombocytopenia, but after the last platelet transfusion his platelet count only
increased from 21,000/µL to 26,000/µL. Does he need crossmatched platelets?
ANSWER
As a general rule of thumb, transfusion of one unit of apheresis platelets or a single pooled unit (“5
pack” or “6 pack”) of whole blood derived platelets is expected to increase an adult’s platelet count
by about 30,000-50,000/µL. If two or more platelet transfusions result in a lower than expected
increase in platelet count, platelet refractoriness should be considered. 
If platelet refractoriness is suspected, pre- and post-transfusion platelet counts should be measured
on at least two separate occasions. The post transfusion platelet count should be drawn 10 to 60
minutes after the platelet transfusion is completed. These values can then be used to calculate the
corrected count increment (CCI):
(Platelet count(post) – platelet count(pre)) x body surface area (m2) 
CCI = —————————————————————————————— 
Number of platelets transfused (x 1011)
A total CCI of less than 5000 indicates platelet refractoriness.
For the scenario in question, the change in platelet count of 5,000 multiplied by an average male
body surface area of 1.9 (m2) divided by the minimum required number of platelets in an apheresis
unit of 3.0 (x 1011) equals 3167, consistent with platelet refractoriness. Units are usually omitted
when reporting the CCI result.
Platelet refractoriness may be caused by a variety of immune-mediated or nonimmune causes.
Nonimmune mechanisms such as infection, fever, bleeding, DIC, splenomegaly and drugs account
for the majority of cases of platelet refractoriness. In these cases, treatment should be aimed at the
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underlying cause whenever possible; crossmatched or HLA matched platelets are of no additional
benefit over random platelets in non-immune cases.
If nonimmune causes have been excluded, the next step is to confirm that the patient received ABO
identical or compatible platelet units. Although platelets do not require ABO matching, they do
express a small number of ABO antigens which may contribute to a decreased count increment in
some cases. If available, ABO compatible platelet units should be requested.
When platelet refractoriness is immune-mediated, it is most commonly caused by antibodies
against HLA class I antigens or platelet specific antigens. In these cases, crossmatched platelets or
HLA-matched platelets may be helpful. Crossmatched platelets can usually be obtained more
quickly than HLA-matched platelets (1-2 days) and can detect HLA, ABO, and platelet specific
antibodies. HLA-matched platelets generally take longer to obtain, but may be considered for
patients who are highly alloimmunized when crossmatch compatible platelets cannot be found. If
immune-mediated platelet refractoriness is suspected, consult your blood bank pathologist to
determine if crossmatched or HLA matched platelets may be an option for your patient.
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